CLL breakthrough: shorter treatment may be safer and just as effective

NCT ID NCT04722172

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely stop taking acalabrutinib and obinutuzumab once their cancer responds very well, instead of continuing treatment indefinitely. The goal is to reduce serious side effects and prevent drug resistance. About 55 participants will receive the drugs and then be monitored closely after stopping treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

Hackensack Meridian Health (Data collection only)

Hackensack, New Jersey, 07601, United States
Memorial Sloan Kettering Basking Ridge (All protocol activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (All protocol activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (All protocol activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All protocol activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (All protocol activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.